Amerikanische Gesellschaft für Hirudotherapie

Castellaniella hirudinis sp. nov., isolated from the skin of Hirudo verbana

Taxonomy paper published in International Journal of Systematic and Evolutionary Microbiology (2012)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomik & ProteomikGlaeser SP, Galatis H, Martin K, Kämpfer P · International journal of systematic and evolutionary microbiology, 2012

Abstract

A Gram-staining-negative, rod-shaped, non-spore-forming bacterium, designated strain E103(T), was isolated from the skin of the medical leech Hirudo verbana. 16S rRNA gene sequence analysis showed that the isolate was closely related to species of the genus Castellaniella. Castellaniella ginsengisoli DCY36(T) was shown to be the most closely related (98.4 % 16S rRNA gene sequence similarity), followed by Castellaniella denitrificans NKNTAU(T) and Castellaniella daejeonensis MJ06(T) (both 97.8 %), then Castellaniella caeni Ho-11(T) (97.5 %). Chemotaxonomic data (major ubiquinone, Q-8; major polar lipids, phosphatidylethanolamine, phosphatidylglycerol and phosphatidylserine; predominant polyamine, putrescine with a moderate amount of 2-hydroxyputrescine; and major fatty acids, C(17 : 0) cyclo, C(16 : 0) and summed feature 4 comprising C(16 : 1)ω7c and/or iso-C(15 : 0) 2-OH) supported the affiliation of the isolate to the genus Castellaniella. DNA-DNA hybridization values with the type strains of all species of the genus Castellaniella were 23 % (reciprocal, 18 %) with C. ginsengisoli KCTC 22398(T), 20 % (26 %) with C. daejeonensis KCTC 22454(T), 11 % (58 %) with C. denitrificans DSM 11046(T) and 13 % (12 %) with C. caeni KCTC 12197(T)(.) Phenotypic differentiation of strain E103(T) from its closest neighbours was possible. Strain E103(T) therefore represents a novel species of the genus Castellaniella, for which the name Castellaniella hirudinis sp. nov. is proposed, with the type strain E103(T) ( = CCUG 62394(T) = LMG 26910(T)).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAlcaligenaceaeAnimalsBacterial Typing TechniquesDNA, BacterialFatty AcidsLeechesMolecular Sequence DataNucleic Acid HybridizationPhylogenyPutrescineRNA, Ribosomal, 16SSequence Analysis, DNA

Zusammenfassung

Polyphasic description of Castellaniella hirudinis sp. nov. (E103T) from medical leech Hirudo verbana skin, contributing to systematic inventory of leech-associated bacteria.

Warum dies für die Hirudotherapie relevant ist

This article reports the isolation and polyphasic taxonomic characterization of a novel bacterial species, Castellaniella hirudinis sp. nov. (strain E103(T)), obtained from the skin of the medicinal leech Hirudo verbana. The study used 16S rRNA sequencing, DNA-DNA hybridization, and chemotaxonomic analyses to establish the strain as a new species within the genus Castellaniella. For ASH's domain, this work contributes to the cataloguing of the culturable bacterial associates of medicinal leeches, which is relevant to understanding leech microbiota and potential infection risks associated with hirudotherapy. However, the study is purely taxonomic in scope — it provides no data on pathogenicity, clinical significance, effects on leech therapy outcomes, or any therapeutic properties of the organism, and thus its relevance to hirudotherapy practice is indirect.

Zitation

Castellaniella hirudinis sp. nov., isolated from the skin of Hirudo verbana.

Glaeser SP, Galatis H, Martin K, Kämpfer P · International journal of systematic and evolutionary microbiology, 2012

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.